![Isabel Aznarez](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Isabel Aznarez
Grundare på
STOKE THERAPEUTICS, INC.
Profil
Isabel Aznarez is the founder of Stoke Therapeutics, Inc. since 2014, holding the title of Senior Vice President & Head-Research.
Dr. Aznarez is currently the Director of Oligonucleotide Therapeutics Society, Inc. since 2019.
Dr. Aznarez obtained a doctorate from the University of Toronto in 2006 and completed an undergraduate degree at Universidad De La Republica Uruguay.
Aktiva positioner av Isabel Aznarez
| Företag | Position | Start |
|---|---|---|
| STOKE THERAPEUTICS, INC. | Grundare | 2014-06-01 |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Direktör/Styrelseledamot | 2019-01-01 |
Isabel Aznarezs utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
88
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Commercial Services |
Universidad De La Republica Uruguay
 Universidad De La Republica Uruguay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stoke Therapeutics, Inc.
 Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
